Alzheimer's Disease International has launched the Alzheimer's Disease Atlas, a platform that pulls together the key indicators used to judge how ready a country is to diagnose, treat and support people with Alzheimer's disease and related dementias. ADI describes it as the first tool of its kind, and the picture it paints is uneven: where a person lives can determine whether they get a timely diagnosis, access to treatment, or any meaningful support at all.
The Atlas, supported by Eli Lilly and Company, is aimed squarely at advocates, policymakers and health system leaders rather than at clinicians alone. The intent is practical - by laying national data side by side, it becomes harder to overlook the countries and populations being left behind, and easier to argue for specific fixes rather than general appeals for more attention to dementia.
One of the more uncomfortable findings is that money alone does not buy readiness. Wealthier nations generally fare better on the indicators, but ADI notes that some of the world's richest countries are still poorly prepared for the increase in dementia expected over the next two decades, when the number of people living with the condition is projected to double.
For families, the significance is straightforward: the systemic gaps the Atlas documents - in diagnostic capacity, treatment access and support services - are the same gaps that leave caregivers navigating dementia largely on their own. Whether a public comparison tool actually shifts national policy remains to be seen, but it gives campaigners a shared set of numbers to work from.